Brought to you by 
Chiron gets DepoTech's DepoCyt cancer therapeutic
24 May 2012
Executive Summary
Chiron acquired exclusive US, Canadian, and European rights to DepoTech's DepoCyt, a tumor therapeutic currently in Phase III for neoplastic meningitis, and will apply Depotech's DepoFoam delivery technology to its own compounds.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Liposomes
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiron gets DepoTech's DepoCyt cancer therapeutic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice